文献速递免疫规划卫生政策与健康促进

美国新冠疫苗安全监测系统概述

Overview of U.S. COVID-19 vaccine safety surveillance systems.
PubMed 文献 · Vaccine · 2024-04-16

美国新冠疫苗接种规划于2020年12月启动,安全监测是其核心组成部分。本报告描述了美国疾控中心、食品药品监督管理局、国防部、退伍军人事务部和印第安人卫生服务局使用的监测系统与项目,并以mRNA新冠疫苗接种后心肌炎为模型,展示多个互补监测系统如何快速发现、评估和验证疫苗安全信号。

要点

  • 美国新冠疫苗安全监测采用被动与主动监测相结合的互补系统。
  • 监测涵盖特殊人群(如孕妇)并对接种后不良事件个案提供临床咨询。
  • 以mRNA疫苗接种后心肌炎为模型,展示多系统快速发现、评估和验证安全信号。

核心结论

  • 美国新冠疫苗安全监测系统在全国接种规划期间展现了及时性和稳健性。

研究设计与样本

  • 本报告描述美国政府新冠疫苗安全监测系统与项目,涉及美国疾控中心、食品药品监督管理局、国防部、退伍军人事务部和印第安人卫生服务局。

主要发现

  • 监测系统包括已建立和新开发的系统,依赖被动(自发报告)和主动监测方法。
  • 对接种后不良事件个案提供临床咨询,并对孕妇等特殊人群开展监测。
  • 以mRNA新冠疫苗接种后心肌炎为模型,展示多个互补监测系统如何快速发现、评估和验证疫苗安全信号。
  • 对接种后心肌炎病例进行了较长期随访以评估恢复状况。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The U.S. COVID-19 vaccination program, which commenced in December 2020, has been instrumental in preventing morbidity and mortality from COVID-19 disease. Safety monitoring has been an essential component of the program. The federal government undertook a comprehensive and coordinated approach to implement complementary safety monitoring systems and to communicate findings in a timely and transparent way to healthcare providers, policymakers, and the public. Monitoring involved both well-established and newly developed systems that relied on both spontaneous (passive) and active surveillance methods. Clinical consultation for individual cases of adverse events following vaccination was performed, and monitoring of special populations, such as pregnant persons, was conducted. This report describes the U.S. government's COVID-19 vaccine safety monitoring systems and programs used by the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, the Department of Defense, the Department of Veterans Affairs, and the Indian Health Service. Using the adverse event of myocarditis following mRNA COVID-19 vaccination as a model, we demonstrate how the multiple, complementary monitoring systems worked to rapidly detect, assess, and verify a vaccine safety signal. In addition, longer-term follow-up was conducted to evaluate the recovery status of myocarditis cases following vaccination. Finally, the process for timely and transparent communication and dissemination of COVID-19 vaccine safety data is described, highlighting the responsiveness and robustness of the U.S. vaccine safety monitoring infrastructure during the national COVID-19 vaccination program.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gee J, Shimabukuro TT, Su JR, et al. Overview of U.S. COVID-19 vaccine safety surveillance systems. Vaccine. 2024. PMID: 38631952. doi:10.1016/j.vaccine.2024.02.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。